EMG
ACHN

Ellington Management Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Ellington Management Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$46K – 949
2017
Q2 		$46K Buy
+10,000
New +$40.2K 0.01% 607
2016
Q4 		– Sell
-37,000
Closed -$300K – 906
2016
Q3 		$300K Buy
+37,000
New +$315K 0.08% 434
2014
Q3 		– Sell
-26,400
Closed -$200K – 525
2014
Q2 		$200K Buy
+26,400
New +$105K 0.09% 361

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Ellington Management Group's ACHN Position: Q3 2017 in Review

Ellington Management Group sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 10,000 shares — an estimated $46K sold.

Ellington Management Group first reported a position in ACHN in Q2 2014 and held it in 3 quarters. The position peaked at $300K in Q3 2016. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

  • Ellington Management Group reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 10,000 Achillion Pharmaceuticals shares in Q3 2017, an estimated $46K.
  • Ellington Management Group first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Ellington Management Group's Achillion Pharmaceuticals position peaked at $300K in Q3 2016.
  • 125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.